Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002
Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001
Inhaled mannitol as treatment for children with cystic fibrosis Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease Year: 2008
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011
Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis Source: Eur Respir J 2011; 37: 1091-1095 Year: 2011
Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency Source: Eur Respir J 2009; 33: 354-360 Year: 2009
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002
Inhaled heparin in cystic fibrosis Source: Eur Respir J 2006; 27: 354-358 Year: 2006
Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study Source: Eur Respir J 2005; 25: 62-68 Year: 2005
Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013
Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study Source: Eur Respir J 2007; 29: 713-719 Year: 2007
Nebulised 7 % hypertonic sodium chloride improves lung function and airway clearance in non cystic fibrosis bronchiectasis Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017